As our understanding of the driver mutations necessary for initiation and progression of cancers improves, we gain critical information on how specific molecular profiles of a tumor may predict responsiveness to therapeutic agents or provide knowledge about prognosis. At our institution a tumor genotyping program was established as part of routine clinical care, screening both hematologic and solid tumors for a wide spectrum of mutations using two next-generation sequencing (NGS) panels: a custom, 33 gene hematological malignancies panel for use with peripheral blood and bone marrow, and a commercially produced solid tumor panel for use with formalin-fixed paraffin-embedded tissue that targets 47 genes commonly mutated in cancer. Our workflow includes a pathologist review of the biopsy to ensure there is adequate amount of tumor for the assay followed by customized DNA extraction is performed on the specimen. Quality control of the specimen includes steps for quantity, quality and integrity and only after the extracted DNA passes these metrics an amplicon library is generated and sequenced. The resulting data is analyzed through an in-house bioinformatics pipeline and the variants are reviewed and interpreted for pathogenicity. Here we provide a snapshot of the utility of each panel using two clinical cases to provide insight into how a well-designed NGS workflow can contribute to optimizing clinical outcomes.
Introduction
Next-generation sequencing (NGS) of clinical oncology specimens has become more widely available over the past several years as growing scientific literature points to the importance of identifying targetable genetic changes and predictive/prognostic molecular markers. Multi-gene panel analyses and whole exome sequencing studies in both epithelial 1, 2 and hematologic 3 malignancies have solidified the concept of tumor heterogeneity and clonal evolution as disease progresses and relapses. Additionally, unlike competing technologies such as polymerase chain reaction (PCR) or Sanger sequencing, NGS can detect most genomic alterations in all clinically relevant cancer genes in a single assay The content for the Heme-NGS Panel was derived from multiple sources, but centers around 16 genes mutated in acute myeloid leukemia (AML) previously described as demonstrating a high level of clinical utility 5 . The Solid-NGS Panel is commercially produced with the targeted regions based upon commonly mutated genes in cancer as reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 6 .
Several key steps characterize the overall workflow for clinical NGS. After the clinician orders the test, a pathologist determines adequacy of the specimen following analysis for tumor percentage and sample volume. In our institution, we require at least 10% tumor due to the background sequencing error rate ("noise") of the technology and the efficiency of the targeted approach. If the tissue is adequate for testing, genomic DNA is extracted. This DNA is then subjected to multiple quality control (QC) steps. If the DNA passes QC, an amplicon library is generated and sequenced. The resulting data is analyzed through an in-house bioinformatics pipeline. Following bioinformatics analysis, variants are manually reviewed and interpreted for pathogenicity before incorporation into a clinical report. Below we describe two cases that went through this rigorous workflow and ultimately led to changes in clinical management.
Case 1 -Acute Myeloid Leukemia
A bone marrow biopsy from patient A was diagnostic for AML, without maturation. Cytogenetic studies were sent on the bone marrow specimen and demonstrated a normal female karyotype. There were 95% circulating blasts present, so a peripheral blood specimen was sent for personalized diagnostic testing on the Heme-NGS Panel.
Acute myeloid leukemia (AML) is a hematological malignancy of the myeloid lineage of white blood cells. The detection of gene mutations in AML has become increasingly important for prognosis and treatment, with recurrent gene mutations recognized as important in pathogenesis and prognosis 7 . Mutations in NPM1 and CEBPA have been associated with a favorable prognostic risk, while internal tandem duplications (ITDs) in FLT3 have been associated with a less favorable outcome 8 . A growing body of evidence supports a pathogenic role for these and other mutations in AML 9 .
Case 2 -Lung Adenocarcinoma
A biopsy of a left supraclavicular mass from patient B demonstrated pulmonary adenocarcinoma. Biopsy material from the formalin-fixed paraffinembedded (FFPE) lymph node mass was sent for genomic testing (Solid-NGS Panel) as rolls/curls with greater than 50% tumor, to identify whether a mutation was present for targeted therapeutic intervention.
Lung cancer is the leading cause of cancer related mortality in the United States and is divided into two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC can be further defined as either adenocarcinoma or squamous cell carcinoma, based on the histology of the lesion. Lung adenocarcinoma is the most common subtype of lung cancer, seen in both smokers and non-smokers, and is the most common form of lung cancer for non-smokers 10 . Blood WBC > 200,000 100 μl * For Blood WBC < 12,000, take 2 ml of blood Table 1 : Blood/Bone Marrow Volume to Use Chart. Since the white blood cell count will vary from sample to sample, it is difficult to specify a specific volume of blood to use. Therefore, the amount of blood to use for the assay must be determined by looking at the white blood cell count (WBC) prior to starting the assay. Although less blood is utilized, it should still be treated as if its 1 ml since the volume of blood used is reduced because the number of cells present is greater than normal.
2. Follow the commercially available kit's protocol to isolate the genomic DNA.
DNA Extraction from Formalin-fixed Paraffin-embedded (FFPE) Tissue
1. Based on the tumor region the pathologist circled on the H&E slide, line up the unstained slides with the guide H&E slide and outline a similar area for extraction. For macro-dissection, process only one specimen/patient's set of slides at a time. 2. Heat the slides on a 45 °C heat block to slightly melt the paraffin. Carefully scrape the tissue within the lines that are marked on the slide, using a new scalpel for each specimen to be extracted. Place the wax scrapings into the appropriately labeled 1.5 ml tube. Be careful because the scraped wax is very electrostatic and may jump out of the tube. 3. Add 320 µl of Deparaffinization Solution for every five to six 5 µm sections (25 -30 µm total). For example, if a tube containing 3 sections of a 10 µm roll/curl is going to be processed, then use 320 µl, but if 5 sections at the same thickness were obtained then use 640 µl. 4. Vortex vigorously for at least 10 sec and perform a quick spin in a microcentrifuge to remove the tissue/wax from the sides and cap and into the solution. Incubate at 56 °C for 3 min., and then incubate at RT for 5 -10 min. 5. Following the RT incubation, add 180 µl of ATL buffer for every 320 µl of Deparaffinization Solution added. Mince the tissue ten times using a sterile mini-pestle using a new pestle for each specimen. Ensure there is no tissue stuck to the pestle, as it can be very sticky. Vortex the suspension vigorously for 3 sec, then centrifuge at maximum speed for 1 min. 6. Add 10 µl of Proteinase K to the lower clear phase. Mix gently by pipetting up and down to ensure the tissue is resuspended. Do NOT vortex.
Incubate at 56 °C overnight with shaking at 400 -500 rpm. vigorously at high speed for 30 sec to uniformly mix the lysis buffers. Incubate on ice for 5 min or the samples can stay on ice for up to an hr. 12. Centrifuge at 5,000 x g for 5 min. The precipitated protein should form a tight, white pellet. Pour the supernatant into a labeled 1.5 ml tube, and then incubate the samples on ice for at least 3 min. Centrifuge at 5,000 x g for 3 min. 13. Add 200 µl of 2-propanol (Isopropanol) for every 180 µl of Buffer ATL added earlier to a labeled 1.5 ml tube (it might be necessary to use a 2 ml tube). For example, if doing three rolls add 600 µl of isopropanol. Add 1 µl of glycogen for every 180 µl of Buffer ATL added earlier to the isopropanol and invert the tube several times to mix. 14. Carefully add the supernatant from the Protein Precipitation step into the Isopropanol mixture. Mix the tube by inverting gently at least 50 times. 15. Centrifuge at maximum speed for 3 min. The DNA will be visible as small white pellet at the bottom of the tube. 16 . Pour or aspirate off the supernatant into the appropriate waste tube. Keep a separate 1.5 ml waste tube for each specimen in case the pellet comes dislodged so it will not be lost or mixed with the waste of other specimens. Drain the tube on a paper towel and ensure the majority of the Isopropanol is removed. 17. Add 300 µl of freshly made 70% ethanol. Invert the tube gently several times to wash the pellet. Try to ensure the pellet comes dislodged to ensure a more thorough cleaning. 18. Centrifuge at maximum speed for 5 min. and then carefully remove the ethanol. The pellet may be loose, so pour or aspirate slowly and watch the pellet. Remove the excess ethanol from the inside of the tube, without touching the pellet. Allow the samples to air dry for 5 -15 min, being careful to not over dry the sample. 19. Add between 25 -100 µl of DNA Hydration Solution to each sample based on the size of the DNA pellet and the starting amount of tissue.
Vortex the tubes vigorously and briefly spin in a microcentrifuge. Incubate for 1 hr at 65 °C to fully rehydrate the DNA.
Genomic DNA Quality Control
Note: There are three independent steps for DNA quality control (QC). See Table 2 for further explanation of why each QC step is performed. The DNA in lane G2 is degraded or fragmented and will not work in the assay. Lanes E1, F1, G1, H1, D2, H2 represent DNA which falls in the 'gray zone' meaning that the assay might work well, but some of the DNA could be too damaged or cross-linked and thus it will not perform well in the assay. Please click here to view a larger version of this figure. 3. PCR Purification and Bead-Based Normalization 1. Remove the magnetic purification beads, Elution Buffer (EBT), and gel-electrophoresis reagents from the 4 °C fridge and place at RT at least 20 min before the next stage. 2. Once the PCR is complete, centrifuge at 1,000 x g for 1 min at 20 °C to collect condensation. Transfer 1 µl of each PCR reaction to strip tubes/plate wells containing 4 µl of water to dilute the samples 1/5. Pipette up and down to mix. 3. Add 2 µl of the diluted PCRed samples to 2 µl of microfluidic-gel buffer. Seal the strips/plate. Shake at 1,800 rpm for at least 30 sec and centrifuge at 1,000 x g for 30 sec. Following manufacturer's protocol, run the mixture on a microfluidic gel to assess if the library preparation yielded an acceptable library (see Figure 3 ). 4. Vortex the magnetic purification beads until they are well-suspended and the color appears homogeneous. Add 45 µl of the beads to each sample. 5. Seal the plate with clear adhesive film and shake the plate at 1,800 rpm for 2 min. Incubate at room temperature without shaking for 10 min. 6. Place the plate onto a magnetic stand. Once the supernatant has cleared, carefully remove and discard the supernatant. If any beads are inadvertently aspirated into the tips, dispense the beads back to the plate and let the plate rest on the magnet for 2 min and confirm that the supernatant has cleared. 7. With the plate on the magnetic stand, add 200 µl of freshly prepared 80% ethanol to each sample well. Move the plate back and forth a few times. Incubate the plate on the magnetic stand for 30 sec. Carefully remove and discard the supernatant. Repeat for a total of two washes. 8. Remove the excess ethanol by briefly centrifuging the plate at 1,000 x g to drive down any ethanol on the tube sides, placing the plate back onto the magnetic stand, and using a p10 multi-channel pipette set to 10 µl to remove the ethanol. Allow the beads to air-dry for 5 -8 min. 9. Using a p100 multi-channel pipette, add 30 µl of EBT to each well. Pipette up and down a few times to ensure the beads come off the side of the tube. Seal the plate with clear adhesive film and shake the plate at 1,800 rpm for 2 min. Both contain formamide]. In addition, get ice for a later step and ensure a heat block suitable for 1.5 ml centrifuge tubes is set to 96 °C. 15. When the 30 min mixing step is complete, place the LNP on a magnetic stand. Once the supernatant has cleared, use a multi-channel pipette to carefully remove and discard the supernatant into the appropriate waste container. 16. Remove the LNP from the magnetic stand and wash the beads with Library Normalization Wash 1 (LNW1) as follows:
Amplicon Library Preparation
1. Add 45 µl of LNW1 to each sample well. CAUTION: Contains formamide. Seal the plate with clear adhesive film and shake the plate at 1,800 rpm for 5 min. Repeat for a total of two washes. Ensure to remove all the LNW1 after the second wash.
17. Remove the LNP from the magnetic stand and, using a multi-channel pipette, add 30 µl of 0.1 N NaOH (less than a week old) to each well to elute the sample. Seal the plate with clear adhesive film and shake the plate at 1,800 rpm for 5 min. Quality control of each step in the process is necessary to ensure the sequencing will yield results such that pre and post sequencing metrics are considered. Appropriate specimen treatment is essential for high quality DNA. Blood and bone marrow in inappropriate fixatives can yield low quality DNA. Inappropriate fixation of solid tumor specimens can degrade DNA (e.g., fixation in B5). DNA quality should be assessed for protein and RNA contamination by spectrophotometric means, and accurately assessed for the amount and integrity of DNA. The sequencing metrics need to be empirically determined in the sequencing laboratory and followed for each sequencing reaction and every specimen. Prior to reporting the sequencing results for each specimen should be assessed for coverage, depth, and adequate performance of positive and negative controls. Please click here to view a larger version of this figure. Coverage Below 250x -Amplicon Number 8 0 Table 3 : Sequencing Run QC Metrics. This is a summary of the most important run statistics, not including the mean coverage, that are used for data review to determine if a library prep sample has passed QC. The whole process is successful if all the percentages are above 90%, but it is possible, with carryover of SW1 or UB1 in the FPU washing step or primer cross-talk, to have lower 'Percent on Target' in the range of 80 -90%. If the 'Percent Mapped' is too low, that would indicate a contamination of bacteria or other DNA, as all samples should align to human. When any of these specifications are below 80%, the sample is flagged for further review to help determine how to proceed and improve the process. , and lastly what samples are associated with certain indexes (in this case dual indexing). The parts that are highlighted in yellow can be changed to whatever the experimenter wants, but in this case the lab uses these parameters. Please click here to download this figure.
Percentage of Reads Mapping

Discussion
As the two NGS tests described in this manuscript are offered clinically, the most important practical consideration is quality control. Specifically, close consideration must be paid to the quality and quantity of extracted DNA. This is especially important for FFPE samples which are often highly degraded with variable DNA yield. An isopropanol precipitation method was developed in order to maximize DNA yield from FFPE samples as column-based methods were found to sometimes lead to DNA shearing with limited elution volumes. Therefore, most of the time when a specimen yields too low concentration or is too degraded for the assay, it is most likely due to the tissue size, type, or fixation and not the extraction process. For blood/bone marrow specimens, if there is an extraction failure, it is usually due to a sample being hemodilute (i.e., not having sufficient number of white blood or tumor cells in that draw) or chemo ablated.
During validation, cutoffs for acceptability of DNA quality and quantity should be established. The recommended input of 100 -250 ng is often used in the assay; however, if the DNA quality is good, then lower input amounts can be successful. In addition, if the DNA quality is poor (i.e., the amount of amplifiable DNA is less than 100 -250 ng) then higher input amounts can improve the quality of the sequencing results (since the amount of amplifiable DNA will reach the recommended input). Metrics for DNA quality and quantity should be applied to each sample before advancing the DNA into library preparation. Those samples in a "gray zone" (see Figure 2) should be run at the discretion of the laboratory director or designee. Currently the best way to predict if the DNA will not perform well during sequencing is to perform a qPCR-based assay that allows for the quantification and quality assessment of input DNA. This approach addresses the bioavailability of different sized fragments in the specimen, through the amplification of different sized fragments (e.g., 100 bp, 150 bp, 200 bp and 300 bp) and comparison yield.
Currently, library preparation involves a large number of manual steps where a misstep at one of several junctures can cause the library to either fail or to be of poor quality. The microfluidic gel analysis is the only QC step to check a library prep issue before sequencing. Accordingly, there are several critical steps where extra mindfulness can increase the probability of a successful reaction. It is imperative to guarantee the correct sample and oligonucleotide pool are used for each specimen. Ensuring and properly recording that each sample contains one of 96 unique combinations of dual-indexed PCR primer pairs reduces chance for a sample mix up. Also, it is important to ensure the filter plate (FPU) drains correctly; if it does not drain appropriately this can cause the extension-ligation step of the library preparation to perform suboptimally and lead to poor quality sequencing data. After library QC, it is critical to ensure that the LNB1 beads are fully resuspended and that the LNB1/LNA1 solution is well mixed before adding it to the samples as the concentration of this mixture is used to determine the molarity of the library. Finally, if the bead elution step leads to a suboptimal amount of library eluting off the beads it will decrease clustering density and possibly cause the library to not obtain adequate mean coverage. Conversely, an excess of library will lead to poorer quality reads. Therefore, it is important to be consistent at the bead-based normalization step to ensure optimal pooling and clustering of the libraries on the sequencer.
In addition to library preparation, it is critical to validate a bioinformatics pipeline that will produce accurate mutation calls from the raw, demultiplexed fastq files. Choosing a custom solution may be time-consuming as there are many open source and commercially-available aligners, variant callers, and NGS software packages that one would have to sift through. Custom algorithms will need to be designed to extract essential performance statistics, identify unique recurring mutations that eluded most open source tools, and determine copy number status over each of the loci. During the validation process of a bioinformatics pipeline, it is important to determine the reportable cutoffs for variants that meet or exceed both a minimum depth of coverage after quality filtering (e.g., a minimum of 250 reads) and a minimum allele frequency (e.g., 4%). Since this a multiplexed amplicon-based assay, it is important to determine the minimum mean depth of coverage (e.g., 1,000x) that the library needs to achieve to be able to get the lowest performing amplicon to the minimum depth of reads. In addition, the multiplexed nature of the assay does cause off target effects and these 'artifacts' will need to be discovered and fully vetted before launch. Another important limitation to the described assay is a need for samples to contain greater than 10% tumor in order to achieve the validated minimum allele frequency.
The detection of low frequency, 1%, FLT3 insertions is evidence that manual review is still desirable in this process. Even with an allele frequency cut-off of 5%, some important mutations maybe missed and thus manual review will be essential to ascertain these variants. For FLT3-ITDs, visual inspection of exon 14 is performed for all AML patients to ensure a low level or large insertion/duplication does not go unnoticed.
In addition, HER2 exon 20 insertions that are commonly next to the primer sequence, need manual intervention. Despite having a robust bioinformatics pipeline, some variants could go overlooked which is just the nature of having a hard cutoff for most the stats mentioned above. Better bioinformatics would be needed to help alleviate this issue, as will better library preparation and/or sequencing methodologies, because it is more advantageous to have good quality data at even lower cutoffs that contain fewer artifacts and false positives.
The detection and interpretation of allele frequencies can be difficult due to the difficulty in tumor percentage determination and amplification bias of some regions of the genome. In addition, allele frequencies over 50% can be detected, as observed in case 2. This is interpreted as a loss of heterozygosity (LOH) event, either due to loss of the normal allele, leading to the apparent increase of mutant reads, a gain of the mutant allele (e.g., 2 mutant and one normal copy) or other mechanisms. These mechanisms can be elucidated by utilizing array comparative genomic hybridization (aCGH 19 ) and/or a SNP genotyping array.
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The current target enrichment methodologies rely on full-day procedures of either inefficient hybrid capture or multiplexed PCR techniques that result in the need for more sequencing coverage of a single sample and more off target sequencing reads. Additional applications for NGS molecular oncology expected in the near future will include easier library preparation methods that can be fully automatable and be able to process samples with very low amounts of input DNA (i.e., less than 1 ng) as well as samples with highly degraded DNA. To address these challenges, most methods will presumably be PCR based, either being a multistep PCR approach or a massively-parallel singleplex PCR approach. In addition, molecular barcoding of individual amplicons has been shown to dramatically reduce background sequencing noise and will enable testing of samples with lower proportions of tumor cells to achieve lower allele frequencies and move towards capturing circulating tumor cells.
Detection of disease-associated mutations in cancer specimens has been standard of care for decades. Historically, genes were often tested sequentially, one gene/exon at a time, with the identification of a mutation leading to the end of the testing sequence. The advent of NGS has allowed for a less biased approach to sequencing multiple genes associated with many cancers in parallel leading to the identification of multiple mutations that are associated with neoplasia. The clinical utility of NGS for the detection of somatic mutations in cancer is increasingly evident. Indeed, NGS-based analysis of tumor samples represents a new paradigm that challenges traditional, single gene testing, but the clinical utility is very clear. Clinical laboratories today have the exciting opportunity to wed careful method validation and test interpretation with the application of this powerful technology.
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